Effects of pre-treatment on odds of immune-related adverse events.

被引：0
|
作者：
Hunting, John
Olson, Eric
Faucheux, Andrew Thomas
Elko, Catherine A.
Knapp, Mary-Peyton
Price, Sarah
Brinton, Stephanie
Lycan, Thomas William, Jr.
机构：
[1] Wake Forest Baptist Med Ctr, Dept Internal Med, Winston Salem, NC USA
[2] Wake Forest Baptist Med Ctr, Dept Hematol & Oncol, Winston Salem, NC USA
[3] Wake Forest Sch Med, Dept Social Sci & Hlth Policy, Winston Salem, NC 27101 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2540
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Atezolizumab/bevacizumabBleeding and immune-related adverse events
    Reactions Weekly, 2024, 1998 (1) : 84 - 84
  • [32] Immune-related adverse events of checkpoint inhibitors
    不详
    Nature Reviews Disease Primers, 6 (1) : 39
  • [33] Immune-related Adverse Events in Cancer Patients
    Pallin, Daniel J.
    Baugh, Christopher W.
    Postow, Michael A.
    Caterino, Jeffrey M.
    Erickson, Timothy B.
    Lyman, Gary H.
    ACADEMIC EMERGENCY MEDICINE, 2018, 25 (07) : 819 - 827
  • [34] Reply to ‘Personalized treatment of immune-related adverse events — balance is required’
    Kashayar Esfahani
    Leonard Calabrese
    Nature Reviews Clinical Oncology, 2020, 17 : 518 - 518
  • [35] Reply to 'Personalized treatment of immune-related adverse events - balance is required'
    Esfahani, Kashayar
    Calabrese, Leonard
    NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (08) : 518 - 518
  • [36] Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events
    Smithy, James W.
    Faleck, David M.
    Postow, Michael A.
    CLINICAL CANCER RESEARCH, 2022, 28 (07) : 1250 - 1257
  • [37] Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review
    Friedman, Claire F.
    Proverbs-Singh, Tracy A.
    Postow, Michael A.
    JAMA ONCOLOGY, 2016, 2 (10) : 1346 - 1353
  • [38] Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors
    Weinmann, Sophia C.
    Pisetsky, David S.
    RHEUMATOLOGY, 2019, 58 : 59 - 67
  • [39] TOCILIZUMAB FOR THE TREATMENT OF IMMUNE-RELATED ADVERSE EVENTS TO IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES
    Campochiaro, C.
    Farina, N.
    Tomelleri, A.
    De Luca, G.
    Cavalli, G.
    Lazzari, C.
    Ferrara, R.
    Garassino, M.
    Gregorc, V.
    Dagna, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 953 - 953
  • [40] Immune-Related Adverse Events From Immune Checkpoint Inhibitors
    Marrone, K. A.
    Ying, W.
    Naidoo, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (03) : 242 - 251
12345